MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- NA
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
- Status
- TERMINATED
- Phase
- N/A
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
- Status
- TERMINATED
- Phase
- PHASE1
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Status
- COMPLETED
- Phase
- PHASE3
Trastuzumab in HER2-positive Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Herzuma-capecitabine/Cisplatin for Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Status
- COMPLETED
- Phase
- PHASE3
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
- Status
- TERMINATED
- Phase
- PHASE2
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1